Influence of the duration of fondaparinux (Arixtra1®) prophylaxis in preventing venous thromboembolism following major orthopedic surgery

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 2, 2003, Pages 383-384

  Eriksson, B I ^a   Bauer, K A ^b   Lassenz, M R ^c   Turpie, A G G ^d  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c HILLERØD HOSPITAL   (Denmark)

^d General Division   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; FONDAPARINUX; POLYSACCHARIDE;

CLINICAL TRIAL; DRUG ANTAGONISM; HUMAN; LETTER; MULTICENTER STUDY; ORTHOPEDIC SURGERY; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; THROMBOEMBOLISM; VEIN THROMBOSIS;

FACTOR XA; HUMANS; ORTHOPEDIC PROCEDURES; POLYSACCHARIDES; POSTOPERATIVE COMPLICATIONS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0141450381     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00104.x     Document Type: Letter

References (4)

1. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR, for the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Fondaparinux versus enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 1833-40.
2. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA, Wheeler HB, Sixth ACCP Consensus Conference on antithrombotic therapy. Prevention of venous thromboembolism. Chest 2001; 119 (Suppl.): 132S-175S.
3. Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE, Ghali WA, Butcher MS, Brant RF, Bergqvist D, Hamulyak K, Francis CW, Marder VJ, Raskob GE. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty. A systematic review. Arch Intern Med 2001; 161: 1952-60.
4. Fitzgerald RH Jr, Spiro TE, Trowbridge AA, Gardiner GA Jr, Whitsett TL,O'Connell MB, Ohar JA,Young TR, for the Enoxaparin Clinical Trial Group. Prevention of venous thromboembolic disease following primary total knee arthroplasty. J Bone Joint Surg Am 2001; 83: 900-6.